Cargando…
Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study
Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678933/ https://www.ncbi.nlm.nih.gov/pubmed/31319547 http://dx.doi.org/10.3390/cancers11070995 |
_version_ | 1783441219802628096 |
---|---|
author | Bhattarai, Shristi Klimov, Sergey Mittal, Karuna Krishnamurti, Uma Li, Xiaoxian (Bill) Oprea-Ilies, Gabriela Wetherilt, Ceyda Sonmez Riaz, Ansa Aleskandarany, Mohammed A. Green, Andrew R. Ellis, Ian O. Cantuaria, Guilherme Gupta, Meenakshi Manne, Upender Agboola, Johnson Baskovich, Brett Janssen, Emiel A. M. Callagy, Grace Walsh, Elaine M. Mehta, Anurag Dogra, Atika Shet, Tanuja Gajaria, Pooja Traina, Tiffany Nggada, Haruna A. Omonisi, Abidemi Ahmed, Saad A. Rakha, Emad A. Rida, Padmashree Aneja, Ritu |
author_facet | Bhattarai, Shristi Klimov, Sergey Mittal, Karuna Krishnamurti, Uma Li, Xiaoxian (Bill) Oprea-Ilies, Gabriela Wetherilt, Ceyda Sonmez Riaz, Ansa Aleskandarany, Mohammed A. Green, Andrew R. Ellis, Ian O. Cantuaria, Guilherme Gupta, Meenakshi Manne, Upender Agboola, Johnson Baskovich, Brett Janssen, Emiel A. M. Callagy, Grace Walsh, Elaine M. Mehta, Anurag Dogra, Atika Shet, Tanuja Gajaria, Pooja Traina, Tiffany Nggada, Haruna A. Omonisi, Abidemi Ahmed, Saad A. Rakha, Emad A. Rida, Padmashree Aneja, Ritu |
author_sort | Bhattarai, Shristi |
collection | PubMed |
description | Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients’ prognosis. Methods: We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222), Nigeria (n = 180), and India (n = 242); total n = 1407}. All TNBC samples were stained with the same anti-AR antibody using the same immunohistochemistry protocol, and samples with ≥1% of AR-positive nuclei were deemed AR-positive TNBCs. Results: AR status shows population-specific patterns of association with patients’ overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. Conclusion: AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted. |
format | Online Article Text |
id | pubmed-6678933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66789332019-08-19 Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study Bhattarai, Shristi Klimov, Sergey Mittal, Karuna Krishnamurti, Uma Li, Xiaoxian (Bill) Oprea-Ilies, Gabriela Wetherilt, Ceyda Sonmez Riaz, Ansa Aleskandarany, Mohammed A. Green, Andrew R. Ellis, Ian O. Cantuaria, Guilherme Gupta, Meenakshi Manne, Upender Agboola, Johnson Baskovich, Brett Janssen, Emiel A. M. Callagy, Grace Walsh, Elaine M. Mehta, Anurag Dogra, Atika Shet, Tanuja Gajaria, Pooja Traina, Tiffany Nggada, Haruna A. Omonisi, Abidemi Ahmed, Saad A. Rakha, Emad A. Rida, Padmashree Aneja, Ritu Cancers (Basel) Brief Report Background: The androgen receptor (AR) has emerged as a potential therapeutic target for AR-positive triple-negative breast cancer (TNBC). However, conflicting reports regarding AR’s prognostic role in TNBC are putting its usefulness in question. Some studies conclude that AR positivity indicates a good prognosis in TNBC, whereas others suggest the opposite, and some show that AR status has no significant bearing on the patients’ prognosis. Methods: We evaluated the prognostic value of AR in resected primary tumors from TNBC patients from six international cohorts {US (n = 420), UK (n = 239), Norway (n = 104), Ireland (n = 222), Nigeria (n = 180), and India (n = 242); total n = 1407}. All TNBC samples were stained with the same anti-AR antibody using the same immunohistochemistry protocol, and samples with ≥1% of AR-positive nuclei were deemed AR-positive TNBCs. Results: AR status shows population-specific patterns of association with patients’ overall survival after controlling for age, grade, population, and chemotherapy. We found AR-positive status to be a marker of good prognosis in US and Nigerian cohorts, a marker of poor prognosis in Norway, Ireland and Indian cohorts, and neutral in UK cohort. Conclusion: AR status, on its own, is not a reliable prognostic marker. More research to investigate molecular subtype composition among the different cohorts is warranted. MDPI 2019-07-17 /pmc/articles/PMC6678933/ /pubmed/31319547 http://dx.doi.org/10.3390/cancers11070995 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Bhattarai, Shristi Klimov, Sergey Mittal, Karuna Krishnamurti, Uma Li, Xiaoxian (Bill) Oprea-Ilies, Gabriela Wetherilt, Ceyda Sonmez Riaz, Ansa Aleskandarany, Mohammed A. Green, Andrew R. Ellis, Ian O. Cantuaria, Guilherme Gupta, Meenakshi Manne, Upender Agboola, Johnson Baskovich, Brett Janssen, Emiel A. M. Callagy, Grace Walsh, Elaine M. Mehta, Anurag Dogra, Atika Shet, Tanuja Gajaria, Pooja Traina, Tiffany Nggada, Haruna A. Omonisi, Abidemi Ahmed, Saad A. Rakha, Emad A. Rida, Padmashree Aneja, Ritu Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study |
title | Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study |
title_full | Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study |
title_fullStr | Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study |
title_full_unstemmed | Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study |
title_short | Prognostic Role of Androgen Receptor in Triple Negative Breast Cancer: A Multi-Institutional Study |
title_sort | prognostic role of androgen receptor in triple negative breast cancer: a multi-institutional study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678933/ https://www.ncbi.nlm.nih.gov/pubmed/31319547 http://dx.doi.org/10.3390/cancers11070995 |
work_keys_str_mv | AT bhattaraishristi prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT klimovsergey prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT mittalkaruna prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT krishnamurtiuma prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT lixiaoxianbill prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT opreailiesgabriela prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT wetheriltceydasonmez prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT riazansa prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT aleskandaranymohammeda prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT greenandrewr prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT ellisiano prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT cantuariaguilherme prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT guptameenakshi prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT manneupender prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT agboolajohnson prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT baskovichbrett prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT janssenemielam prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT callagygrace prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT walshelainem prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT mehtaanurag prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT dograatika prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT shettanuja prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT gajariapooja prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT trainatiffany prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT nggadaharunaa prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT omonisiabidemi prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT ahmedsaada prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT rakhaemada prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT ridapadmashree prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy AT anejaritu prognosticroleofandrogenreceptorintriplenegativebreastcanceramultiinstitutionalstudy |